Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
108M
-
Number of holders
-
172
-
Total shares
-
67M
-
Shares change
-
+2.8M
-
Total reported value, excl. options
-
$2.13B
-
Value change
-
+$100M
-
Put/Call ratio
-
0.78
-
Number of buys
-
89
-
Number of sells
-
-84
-
Price
-
$31.80
Significant Holders of Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) as of Q4 2020
188 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - COMMON STOCK as of Q4 2020.
Intra-Cellular Therapies, Inc. - COMMON STOCK (ITCI) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67M shares
of 108M outstanding shares and own 62.16% of the company stock.
Largest 10 shareholders include FMR LLC (12M shares), VANGUARD GROUP INC (6.48M shares), WASATCH ADVISORS INC (6.33M shares), BlackRock Inc. (5.9M shares), Bellevue Group AG (3.66M shares), MARSHALL WACE, LLP (3.02M shares), SAMLYN CAPITAL, LLC (1.66M shares), STATE STREET CORP (1.61M shares), MILLENNIUM MANAGEMENT LLC (1.59M shares), and CITADEL ADVISORS LLC (1.43M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.